Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2025-05-09 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
国投证券股份有限公司关于深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券之持续督导保荐总结报告书
Capital/Financing Update Classification · 95% confidence The document is a detailed report issued by the sponsoring securities company (国投证券股份有限公司) regarding the continuous supervision and sponsorship of Shenzhen Chipscreen Biosciences Co., Ltd.'s issuance of convertible bonds to unspecified investors. It references regulatory approvals, the issuance and listing of convertible bonds, and the ongoing supervision period ending December 31, 2024. The report includes descriptions of the sponsor's duties, compliance with laws and regulations, review of information disclosure, and the use of raised funds. It is a comprehensive summary report related to the sponsorship and continuous supervision of a convertible bond issuance, which fits the category of Capital/Financing Update (CAP) rather than a full annual report, audit report, or regulatory filing. The document length is 4066 characters, which is substantial and contains substantive content, not just an announcement or certification. Therefore, the best classification is Capital/Financing Update (CAP).
2025-05-09 Chinese
国投证券股份有限公司关于深圳微芯生物科技股份有限公司2024年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2024年度持续督导跟踪报告" (2024 Annual Continuous Supervision Follow-up Report) issued by the sponsor institution for Shenzhen Microchip Biotechnology Co., Ltd. It details the continuous supervision work, risk warnings, financial data, R&D progress, governance, and compliance with fundraising usage. The content is comprehensive, covering the company's operational, financial, and governance status over the year 2024. It is not a full annual report but a continuous supervision follow-up report as required by regulatory bodies (Shanghai Stock Exchange, China Securities Regulatory Commission). The document includes detailed financial data and analysis but is focused on the sponsor's supervision activities and compliance rather than a full standalone annual report or audit report. This type of document aligns with the category of Regulatory Filings (RNS) as it is a regulatory compliance report related to continuous supervision and not a full Annual Report (10-K) or Audit Report (AR). It is also not a short announcement or certification but a substantive regulatory filing. Therefore, the best classification is Regulatory Filings (RNS).
2025-05-08 Chinese
关于 “微芯转债” 预计满足转股价格修正条件的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the expected triggering of a convertible bond's conversion price adjustment condition. It details the bond issuance, regulatory approvals, terms of the convertible bond, the conditions under which the conversion price may be adjusted downward, and the company's obligations to disclose further information if the condition is triggered. The document is an announcement about a potential price adjustment event related to convertible bonds, not a full financial report or detailed financial data. It is a regulatory disclosure informing investors about the possibility of a price adjustment and the procedures that will follow. The document length is about 2013 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as convertible bond price adjustments.
2025-05-07 Chinese
关于2024年度向特定对象发行A股股票摊薄即期回报的风险提示与公司采取填补措施及相关主体承诺（修订稿）的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Microchip Biotech Co., Ltd. regarding the 2024 issuance of A shares to specific investors, focusing on the dilution of immediate returns, risk warnings, and the company's measures to compensate for this dilution. It includes financial impact analysis, assumptions, risk disclosures, necessity and rationality of the issuance, investment projects, personnel and technical reserves, market reserves, and commitments from controlling shareholders and management to fulfill compensation measures. The document is regulatory in nature, related to capital raising and shareholder equity impact, but it is not a full financial report or earnings release. It is a formal announcement about a capital/financing update with detailed disclosures and commitments. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (9262 characters) and content support this classification rather than a brief announcement or a full annual/interim report.
2025-04-25 Chinese
2024年度独立董事述职报告（朱迅）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2024 from Shenzhen Microchip Biotechnology Co., Ltd. It details the independent director's duties, attendance at board and committee meetings, oversight activities, and evaluation of company governance and financial reporting. The content focuses on the independent director's role and performance rather than presenting full financial statements or comprehensive company financial results. It is a detailed report on board/management information, specifically about the independent director's activities and governance oversight. It is not an annual report (10-K), audit report (AR), or other financial report. Therefore, the document fits best under Board/Management Information (MANG). The document length is about 4885 characters, which is sufficient for a detailed report but not a full financial report. Hence, the classification is MANG with high confidence.
2025-04-25 Chinese
国投证券股份有限公司关于深圳微芯生物科技股份有限公司使用剩余超募资金永久性补充流动资金的专项核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed special verification opinion from the sponsor institution (Guotou Securities Co., Ltd.) regarding the use of remaining over-raised funds by Shenzhen Microcore Biotechnology Co., Ltd. It discusses the company's fundraising, approvals by board and shareholders, compliance with regulatory guidelines, and the plan to permanently supplement working capital with the remaining over-raised funds. The document references regulatory guidelines, board and shareholder meetings, and includes audit and sponsor opinions. It is not a full annual or interim financial report, nor an earnings release or call transcript. It is a regulatory compliance and verification report related to capital use, specifically about the use of over-raised funds. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement and compliance document rather than a financial report or announcement of a report. The document length is under 5,000 characters, but it contains substantive content and is not merely an announcement of a report publication. Therefore, the classification is RNS with high confidence.
2025-04-25 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.